Patent application number | Description | Published |
20110301193 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT - Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR. | 12-08-2011 |
20120156197 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS - Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. | 06-21-2012 |
20140134163 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS - Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. | 05-15-2014 |
20140163069 | COMPOSITIONS OF TARGETED DRUG DEVELOPMENT - Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR. | 06-12-2014 |
20140179681 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT - Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR. | 06-26-2014 |
20140194439 | METHODS OF TARGETED DRUG DEVELOPMENT - Provided herein are compounds having anti-proliferative effect. Also provided are compounds that can modulate the activity of multi-domain proteins comprising a dimerization arm and interdomain tether, such as EGFR, where an untethered, extended conformation is the active state and a tethered conformation is the inactive state, resulting in an autoinhibited configuration. Also provided are methods and pharmacophores for identifying such compounds. Other aspects provide methods or therapeutic treatment for proliferative diseases, disorders, or conditions, such as those associated with EGFR. | 07-10-2014 |
20150105412 | COMBINATION THERAPY WITH MDM2 AND EFGR INHIBITORS - Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone. | 04-16-2015 |
Patent application number | Description | Published |
20090015225 | METHOD FOR REGULATING A VOLTAGE AND CIRCUIT THEREFOR - A voltage regulator ( | 01-15-2009 |
20090167365 | METHOD FOR REGULATING A VOLTAGE AND CIRCUIT THEREFOR - A regulator circuit and a method for regulating an output voltage. The regulator circuit includes an undervoltage protection stage capable of operating in a plurality of operating modes. In one mode, the undervoltage protection stage compensates for a low undervoltage appearing in the output voltage and in another mode it compensates for a large undervoltage appearing in the output voltage. When the output voltage has a low undervoltage, a portion of the current from a current source is routed to a feedback network to balance the input voltages of the undervoltage protection stage and to place the voltage regulator in a steady state operating mode. When the output voltage has a large undervoltage, the undervoltage protection stage turns on a current sourcing transistor that cooperates with the current from the current source to quickly charge a compensation capacitor and increase the power appearing at the output of the voltage regulator. | 07-02-2009 |
20090189573 | METHOD FOR REGULATING A VOLTAGE AND CIRCUIT THEREFOR - A voltage regulator having an overload protection circuit and a method for protecting against an output voltage being less than a predetermined level. The voltage regulator has an overload protection circuit coupled between a feedback network and a regulation section. A power factor correction circuit is connected to the regulation section. An output voltage from the power factor correction circuit is fed back to the feedback network, which transmits a portion of the output voltage to the overload protection circuit. If the output voltage is less than the predetermined voltage level, a transconductance amplifier generates a current that sets an overload flag. Setting the overload flag initiates a delay timer. If the delay exceeds a predetermined amount of time, the overload protection circuit shuts down the voltage regulator. | 07-30-2009 |
20120032652 | CIRCUIT FOR GENERATING A CLOCK SIGNAL FOR INTERLEAVED PFC STAGES AND METHOD THEREOF - A method and circuit for generating a clock signal. A power factor correction circuit has n channels operating out of phase and independently. The circuit is able to generate a clock signal for each channel according to the current cycle duration of each channel. | 02-09-2012 |
20120039007 | METHOD FOR PROVIDING OVER CURRENT PROTECTION AND CIRCUIT - A method and circuit for protecting against an over current condition. A conduction time of one or more transistors is reduced during the over current condition. The conduction time is reduced in an amount that is an increasing function of the amount of the over current. The conduction time may be reduced proportionally to the excess current. | 02-16-2012 |
20130322130 | METHOD OF FORMING A POWER SUPPLY CONTROLLER AND STRUCTURE THEREFOR - In one embodiment, a power supply controller is configured to adjust a peak value of a primary current through a power switch responsively to a difference between a demagnetization time and a discharge time of the parasitic leakage inductance of a transformer. | 12-05-2013 |
20140078798 | POWER FACTOR CONTROLLER AND METHOD - In accordance with an embodiment, a converter includes a power factor controller that varies the switching frequency of a switching transistor in accordance with a signal representative of power at the input of the converter. | 03-20-2014 |
20140085947 | OFF-LINE POWER CONVERTER AND INTEGRATED CIRCUIT SUITABLE FOR USE IN SAME - An off-line power converter includes an integrated circuit power factor controller including a multi-function input terminal, a drive terminal for providing a drive signal to a gate of a drive transistor, a processing circuit coupled to the multi-function input terminal and, based on a signal received from the multi-function input terminal, providing at least one current signal representative of a current conducted in the off-line power converter, and at least one voltage signal representative of a voltage provided to a load, and a controller for providing the drive signal selectively in response to the at least one current signal and the at least one voltage signal. | 03-27-2014 |
20150023064 | METHOD OF FORMING A POWER SUPPLY CONTROLLER AND STRUCTURE THEREFOR - In one embodiment, a method of forming a power supply controller includes forming the power supply controller to receive an input signal that is representative of an ac signal, and forming the power supply controller to form an average value of an output current over a period of a drive signal that is formed by the power supply controller to have a waveshape of substantially one of a squared version of the input signal or a waveshape of the input signal. | 01-22-2015 |
20150028916 | METHOD OF AND CIRCUIT FOR BROWN-OUT DETECTION - A circuit and method for detecting a brown-out condition and providing a feed-forward transfer function in a power supply circuit. A comparison circuit is coupled to a delay element through a latch. A second delay element is connected between the first delay element and an input of the latch. The output of the first delay element is connected to a clamping circuit via a logic circuit. A first voltage is compared with a reference voltage to generate a comparison voltage, which is transmitted through the latch and the first delay element. The comparison voltage is monitored at an output of the first delay element. A brown-out condition occurs if the comparison voltage being monitored at the output of the first delay element results from the first voltage being less than the reference voltage. | 01-29-2015 |
Patent application number | Description | Published |
20130028989 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF - Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment. | 01-31-2013 |
20140017786 | SMALL MOLECULE INHIBITORS OF REPLICATION PROTEIN A THAT ALSO ACT SYNERGISTICALLY WITH CISPLATIN - Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC | 01-16-2014 |
20140370121 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF - Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment. | 12-18-2014 |
20150231104 | SMALL MOLECULE INHIBITORS OF REPLICATION PROTEIN A THAT ALSO ACT SYNERGISTICALLY WITH CISPLATIN - Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 μM. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC50 values below 3 μM. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy. | 08-20-2015 |
Patent application number | Description | Published |
20080319273 | In-vitro measurement of catamenial tampon systems - An apparatus for testing of medical products such as a feminine hygiene product, is presented. The apparatus includes a body, a pump and a vaginal canal assembly. The body includes an internal chamber and a bottom surface having a bore open to the internal chamber. The pump provides a fluid to the body. In one embodiment, the fluid is a menses simulant. The vaginal canal assembly includes an interior canal accepting the product. The vaginal canal assembly includes a passage providing the fluid to the interior canal. The apparatus includes a pressure regulator controlling pressure exerted on the vaginal canal assembly from a volume of air within the internal chamber. The apparatus includes a stand. The stand includes a retaining device and a locking device. The locking device cooperates with the retaining device to selectively secure the body in at least one of a rotational position and an angular position. | 12-25-2008 |
20120175803 | IN-VITRO MEASUREMENT OF CATAMENIAL TAMPON SYSTEMS - An apparatus for testing of medical products such as a feminine hygiene product, is presented. The apparatus includes a body, a pump and a vaginal canal assembly. The body includes an internal chamber and a bottom surface having a bore open to the internal chamber. The pump provides a fluid to the body. In one embodiment, the fluid is a menses simulant. The vaginal canal assembly includes an interior canal accepting the product. The vaginal canal assembly includes a passage providing the fluid to the interior canal. The apparatus includes a pressure regulator controlling pressure exerted on the vaginal canal assembly from a volume of air within the internal chamber. The apparatus includes a stand. The stand includes a retaining device and a locking device. The locking device cooperates with the retaining device to selectively secure the body in at least one of a rotational position and an angular position. | 07-12-2012 |
20150105711 | Ergonomic Tampon Applicator - A tampon applicator barrel includes an insertion tip at a forward end of the barrel, a main body section that extends from the insertion tip, and a reverse taper section that is joined to the main body section so that the main body section is between the insertion tip and the reverse taper section. The main body section tapers toward the insertion tip section. The reverse taper section tapers in a direction away from the insertion tip section. A finger grip section extends from the reverse taper section to a plunger receiving end of the barrel opposite the forward end. The barrel is straight from the forward end to the plunger receiving end that receives a plunger. | 04-16-2015 |